Optimizing MRI for detecting meningiomas with low gadolinium doses
Concordance and Accuracy of Magnetic Resonance Imaging in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium
This study is testing if using less gadolinium during MRI scans can help doctors better find meningiomas in adults while keeping patients safe.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild Research network |
| Locations | 10 sites (Bordeaux and 9 other locations) |
| Trial ID | NCT04113395 on ClinicalTrials.gov |
What this trial studies
This study focuses on improving the accuracy of MRI scans in detecting meningiomas, which are brain tumors that arise from the meninges. It aims to optimize MRI sequences while using lower doses of gadolinium contrast to minimize potential risks associated with gadolinium deposits in patients. The study involves patients over 18 years old who are undergoing MRI for screening or follow-up of known meningiomas. Participants will provide consent to take part in this observational study.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are undergoing MRI for screening or follow-up of known meningiomas.
Not a fit: Patients with contraindications for MRI, known hypersensitivity to gadolinium, or severe renal failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer MRI protocols for monitoring meningiomas, reducing the risk of gadolinium-related complications.
How similar studies have performed: While there is ongoing research into optimizing MRI techniques, this specific approach of using lower gadolinium doses for meningioma detection is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age * Patient performing MRI as part of a screening or follow-up of known meningioma * Express consent to participate in the study Exclusion Criteria: * Contraindication for MRI (electrical device, metallic foreign body, claustrophobia) * Known hypersensitivity to the contrast medium (Gadolinium) * Known renal failure: glomerular filtration rate \<30mL/min * Patient benefiting from a legal protection measure * Pregnant or breastfeeding woman
Where this trial is running
Bordeaux and 9 other locations
- CHU de Bordeaux — Bordeaux, France (Not_yet_recruiting)
- CHU de Grenoble — Grenoble, France (Recruiting)
- CHU de Limoges — Limoges, France (Recruiting)
- CHU de Lyon — Lyon, France (Recruiting)
- CHU de Nantes — Nantes, France (Recruiting)
- Fondation ophtalmique Adolphe de Rothschild — Paris, France (Recruiting)
- CHU de Rennes — Rennes, France (Not_yet_recruiting)
- CHU de Rouen — Rouen, France (Not_yet_recruiting)
- CHU de Strasbourg — Strasbourg, France (Not_yet_recruiting)
- CHU de Tours — Tours, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Amelie YAVCHITZ, PhD
- Email: ayavchitz@for.paris
- Phone: 0148036454
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.